Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 523


Monotherapeutically nonactive CTLA-4 blockade results in greatly enhanced antitumor effects when combined with tumor-targeted superantigens in a B16 melanoma model.

Sundstedt A, Celander M, Eriksson H, Törngren M, Hedlund G.

J Immunother. 2012 May;35(4):344-53. doi: 10.1097/CJI.0b013e318253ec25.


Immunotherapy with tumor-targeted superantigens (TTS) in combination with docetaxel results in synergistic anti-tumor effects.

Sundstedt A, Celander M, Ohman MW, Forsberg G, Hedlund G.

Int Immunopharmacol. 2009 Aug;9(9):1063-70. doi: 10.1016/j.intimp.2009.04.013.


Combining tumor-targeted superantigens with interferon-alpha results in synergistic anti-tumor effects.

Sundstedt A, Celander M, Hedlund G.

Int Immunopharmacol. 2008 Mar;8(3):442-52. doi: 10.1016/j.intimp.2007.11.006.


Antibody-targeted superantigens are potent inducers of tumor-infiltrating T lymphocytes in vivo.

Dohlsten M, Hansson J, Ohlsson L, Litton M, Kalland T.

Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9791-5.


Adenovirus-mediated intratumoral lymphotactin gene transfer potentiates the antibody-targeted superantigen therapy of cancer.

Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, Yao H, Zhang W, Wang J, Cao X.

J Mol Med (Berl). 2002 Sep;80(9):585-94.


Intratumoral IL-18 gene transfer improves therapeutic efficacy of antibody-targeted superantigen in established murine melanoma.

Wang Q, Yu H, Ju DW, He L, Pan JP, Xia DJ, Zhang LH, Cao X.

Gene Ther. 2001 Apr;8(7):542-50.


Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.

Li B, VanRoey M, Wang C, Chen TH, Korman A, Jooss K.

Clin Cancer Res. 2009 Mar 1;15(5):1623-34. doi: 10.1158/1078-0432.CCR-08-1825.


Vaccination with IL-18 gene-modified, superantigen-coated tumor cells elicits potent antitumor immune response.

Wang Q, Yu H, Zhang L, Ju D, Pan J, Xia D, He L, Wang J, Cao X.

J Cancer Res Clin Oncol. 2001 Dec;127(12):718-26.


CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma.

Wu L, Yun Z, Tagawa T, Rey-McIntyre K, de Perrot M.

Mol Cancer Ther. 2012 Aug;11(8):1809-19. doi: 10.1158/1535-7163.MCT-11-1014.


Immune response during tumor therapy with antibody-superantigen fusion proteins.

Rosendahl A, Hansson J, Sundstedt A, Kalland T, Dohlsten M.

Int J Cancer. 1996 Sep 27;68(1):109-13.


The distinct role of CD4+ and CD8+ T-cells during the anti-tumour effects of targeted superantigens.

Litton MJ, Dohlsten M, Rosendahl A, Ohlsson L, Søgaard M, Andersson J, Andersson U.

Br J Cancer. 1999 Sep;81(2):359-66.


Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.

Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, Toes RE, Offringa R, Melief CJ.

J Exp Med. 2001 Sep 17;194(6):823-32.


Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals.

Mitsui J, Nishikawa H, Muraoka D, Wang L, Noguchi T, Sato E, Kondo S, Allison JP, Sakaguchi S, Old LJ, Kato T, Shiku H.

Clin Cancer Res. 2010 May 15;16(10):2781-91. doi: 10.1158/1078-0432.CCR-09-3243.


Cytotoxic T lymphocyte antigen-4 blockade enhances antitumor immunity by stimulating melanoma-specific T-cell motility.

Pentcheva-Hoang T, Simpson TR, Montalvo-Ortiz W, Allison JP.

Cancer Immunol Res. 2014 Oct;2(10):970-80. doi: 10.1158/2326-6066.CIR-14-0104.


A superantigen-antibody fusion protein for T-cell immunotherapy of human B-lineage malignancies.

Gidlöf C, Dohlsten M, Lando P, Kalland T, Sundström C, Tötterman TH.

Blood. 1997 Mar 15;89(6):2089-97.


Treatment with tumor-reactive Fab-IL-2 and Fab-staphylococcal enterotoxin A fusion proteins leads to sustained T cell activation, and long-term survival of mice with established tumors.

Søgaard M, Ohlsson L, Kristensson K, Rosendahl A, Sjoberg A, Forsberg G, Kalland T, Dohlsten M.

Int J Oncol. 1999 Nov;15(5):873-82.


Perforin and IFN-gamma are involved in the antitumor effects of antibody-targeted superantigens.

Rosendahl A, Kristensson K, Hansson J, Riesbeck K, Kalland T, Dohlsten M.

J Immunol. 1998 Jun 1;160(11):5309-13.

Items per page

Supplemental Content

Support Center